Pharmacotherapeutic Approaches in Oral Medicine

  • Sandra Goncalves
  • Ray A. Dionne
  • Geraldine Moses
  • Marco CarrozzoEmail author
Reference work entry


While the management of oral and maxillofacial diseases continues to progress, clinicians continue to use a constantly expanding range of medications and thus must be aware of their adverse effects, interactions, and dosages. The aim of this chapter is to provide a concise and evidence-based guide to the pharmacotherapeutic management of common oral and maxillofacial diseases. It must be acknowledged however, that in many instances, prescriptions for oral medicine conditions are used off-label, and mostly based on expert opinion and experience. This chapter is divided into three sections. Firstly, it will discuss the principal pharmacological profile of topical and systemic antibacterials, antiseptics, salivary substitutes and sialogogues, antifungals, antivirals, immunosuppressive, anti-inflammatory, and biologic drugs. Secondly, concise therapeutic protocols will give clinicians practical guidance on the management of the most common oral diseases treated in oral medicine. The final part of this chapter discusses the main drugs used for the management of orofacial pain.


Pharmacotherapeutics Oral medicine Topical and systemic Antibacterial Antiseptics Salivary substitutes Sialogogues Antifungals Antivirals Immunosuppressive Anti-inflammatory Biologics drugs Facial pain 


  1. Aframian DJ, Helcer M, Livni D, Robinson SD, Markitziu A, Nadler C. Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis. 2007;13(1):88–92.PubMedCrossRefGoogle Scholar
  2. Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015;14(4):323–31.PubMedCrossRefGoogle Scholar
  3. Aizpurua-Olaizola O, Omar J, Navarro P, Olivares M, Etxebarria N, Usobiaga A. Identification and quantification of cannabinoids in Cannabis sativa L. plants by high performance liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2014;406(29):7549–60.PubMedCrossRefGoogle Scholar
  4. Al Johani KA, Hegarty AM, Porter SR, Fedele S. Calcineurin inhibitors in oral medicine. J Am Acad Dermatol. 2009;61(5):829–40.PubMedCrossRefGoogle Scholar
  5. Alajbeg I, Rogulj AA, Hutinec Z. Orofacial granulomatosis treated with intralesional triamcinolone. Acta Dermatovenerol Croat. 2011;19(3):165–9.PubMedGoogle Scholar
  6. Amos K, Yeoh SC, Farah CS. Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: a retrospective pilot study. J Orofac Pain. 2011;25(2):125–30.PubMedGoogle Scholar
  7. Andrade P, Lopes S, Albuquerque A, Osorio F, Pardal J, Macedo G. Oral Lichen Planus in IBD Patients: A Paradoxical Adverse Effect of Anti-TNF-alpha Therapy. Dig Dis Sci. 2015;60(9):2746–9.PubMedCrossRefGoogle Scholar
  8. Ang CW, Jarrad AM, Cooper MA, Blaskovich MAT. Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases. J Med Chem. 2017;60(18):7636–57.PubMedCrossRefGoogle Scholar
  9. Anstey AV, Wakelin S, Reynolds NJ, British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol. 2004;151(6):1123–32.PubMedCrossRefGoogle Scholar
  10. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248(Suppl 1):3–10.PubMedCrossRefGoogle Scholar
  11. Arduino PG, Porter SR. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral Dis. 2006;12(3):254–70.PubMedCrossRefPubMedCentralGoogle Scholar
  12. Arduino PG, Carbone M, Della Ferrera F, Elia A, Conrotto D, Gambino A, Comba A, Calogiuri PL, Broccoletti R. Pimecrolimus vs. tacrolimus for the topical treatment of unresponsive oral erosive lichen planus: a 8 week randomized double-blind controlled study. J Eur Acad Dermatol Venereol. 2014;28(4):475–82.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, Massarotti EM, Bush ML. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009;61(1):104–11.PubMedCrossRefGoogle Scholar
  14. Attal N, Brasseur L, Chauvin M, Bouhassira D. Effects of single and repeated applications of a eutectic mixture of local anaesthetics (EMLA) cream on spontaneous and evoked pain in post-herpetic neuralgia. Pain. 1999;81(1–2):203–9.PubMedCrossRefGoogle Scholar
  15. Atzmony L, Hodak E, Leshem YA, Rosenbaum O, Gdalevich M, Anhalt GJ, Mimouni D. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):264–71.PubMedCrossRefGoogle Scholar
  16. AusDI. Lidocaine (Topical) – indipendent professional monograph. 2018Google Scholar
  17. Baccaglini L, Lalla RV, Bruce AJ, Sartori-Valinotti JC, Latortue MC, Carrozzo M, Rogers RS 3rd. Urban legends: recurrent aphthous stomatitis. Oral Dis. 2011;17(8):755–70.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Baker JS, Nolan PJ. Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: A case series. J Am Dent Assoc. 2017;148(1):33–9.PubMedCrossRefGoogle Scholar
  19. Balasubramaniam R, Ram S. Orofacial movement disorders. Oral Maxillofac Surg Clin North Am. 2008;20(2):273–85, viiPubMedCrossRefGoogle Scholar
  20. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006;533(1–3):2–14.PubMedCrossRefGoogle Scholar
  21. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther. 2007;20(4):216–28.PubMedCrossRefGoogle Scholar
  22. Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010;120(2–3):69–75.PubMedCrossRefGoogle Scholar
  23. Beacher N, Sweeney MP, Bagg J. Dentists, antibiotics and Clostridium difficile-associated disease. Br Dent J. 2015;219(6):275–9.PubMedCrossRefGoogle Scholar
  24. Becker DE. Antimicrobial drugs. Anesth Prog. 2013;60(3):111–22; quiz 123PubMedPubMedCentralCrossRefGoogle Scholar
  25. Becker JC, Houben R, Vetter CS, Brocker EB. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer. 2006;6:7.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Bennett M. Neuropathic pain. Oxford Pain Management Library. Oxford: Oxford University Press; 2010.CrossRefGoogle Scholar
  27. Birkeland IW Jr, Clawson DK. Drug combinations with orphenadrine for pain relief associated with muscle spasm. Clin Pharmacol Ther. 1968;9(5):639–46.PubMedCrossRefGoogle Scholar
  28. Borenstein DG, Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther. 2003;25(4):1056–73.PubMedCrossRefGoogle Scholar
  29. Brewer JD, Colegio OR, Phillips PK, Roenigk RK, Jacobs MA, Van de Beek D, Dierkhising RA, Kremers WK, McGregor CG, Otley CC. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol. 2009;145(12):1391–6.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Brocklehurst P, Tickle M, Glenny AM, Lewis MA, Pemberton MN, Taylor J, Walsh T, Riley P, Yates JM. Systemic interventions for recurrent aphthous stomatitis (mouth ulcers). Cochrane Database Syst Rev. 2012;9:CD005411.Google Scholar
  31. Canavan D, Graff-Radford SB, Gratt BM. Traumatic dysesthesia of the trigeminal nerve. J Orofac Pain. 1994;8(4):391–6.PubMedGoogle Scholar
  32. Carbone M, Goss E, Carrozzo M, Castellano S, Conrotto D, Broccoletti R, Gandolfo S. Systemic and topical corticosteroid treatment of oral lichen planus: a comparative study with long-term follow-up. J Oral Pathol Med. 2003;32(6):323–9.PubMedCrossRefGoogle Scholar
  33. Carr AJ, Ng WF, Figueiredo F, Macleod RI, Greenwood M, Staines K. Sjogren's syndrome - an update for dental practitioners. Br Dent J. 2012;213(7):353–7.PubMedCrossRefGoogle Scholar
  34. Carrozzo M, Arduino P, Bertolusso G, Cozzani E, Parodi A. Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report. Int J Oral Maxillofac Surg. 2009;38(10):1071–6.PubMedCrossRefGoogle Scholar
  35. Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol. 2009;58(10):519–37.PubMedGoogle Scholar
  36. Chahin S, Berger JR. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. J Neurovirol. 2015;21(6):623–31.PubMedCrossRefGoogle Scholar
  37. Chan KK, Glenny AM, Weldon JC, Furness S, Worthington HV, Wakeford H. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. Cochrane Database Syst Rev. 2015;12:CD010341.Google Scholar
  38. Chao TJ. Adalimumab in the management of cutaneous and oral lichen planus. Cutis. 2009;84(6):325–8.PubMedGoogle Scholar
  39. Cholera M, Chainani-Wu N. Management of Pemphigus Vulgaris. Adv Ther. 2016;33(6):910–58.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain. 2003;19(1):59–68.PubMedCrossRefGoogle Scholar
  41. Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7):480–92.PubMedCrossRefGoogle Scholar
  42. Cirillo N, Cozzani E, Carrozzo M, Grando SA. Urban legends: pemphigus vulgaris. Oral Dis. 2012;18(5):442–58.PubMedCrossRefGoogle Scholar
  43. Clark GT, Dionne RA. Orofacial pain. Chichester: Wiley Blackwell; 2012.CrossRefGoogle Scholar
  44. Clark GT, Padilla M, Dionne R. Medication Treatment Efficacy and Chronic Orofacial Pain. Oral Maxillofac Surg Clin North Am. 2016;28(3):409–21.PubMedCrossRefGoogle Scholar
  45. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.PubMedCrossRefGoogle Scholar
  46. Conrotto D, Carbone M, Carrozzo M, Arduino P, Broccoletti R, Pentenero M, Gandolfo S. Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial. Br J Dermatol. 2006;154(1):139–45.PubMedCrossRefGoogle Scholar
  47. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G Jr. Prevention of bacterial endocarditis: recommendations by the American Heart Association. J Am Dent Assoc. 1997;128(8):1142–51.PubMedCrossRefGoogle Scholar
  48. Davies AN, Thompson J. Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database Syst Rev. 2015;10:CD003782.Google Scholar
  49. De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol. 2009;23(3):281–91.PubMedPubMedCentralCrossRefGoogle Scholar
  50. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol. 2004;30(2):115–33.PubMedCrossRefGoogle Scholar
  51. De la Torre Canales G, Camara-Souza MB, do Amaral CF, Garcia RC, Manfredini D. Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. Clin Oral Investig. 2017;21(3):727–34.PubMedCrossRefGoogle Scholar
  52. Decani S, Federighi V, Baruzzi E, Sardella A, Lodi G. Iatrogenic Cushing's syndrome and topical steroid therapy: case series and review of the literature. J Dermatolog Treat. 2014;25(6):495–500.PubMedCrossRefGoogle Scholar
  53. Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain. 2000;16(3):205–8.PubMedCrossRefGoogle Scholar
  54. Dhaliwal S, Jain S, Singh HP, Tiwary AK. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. AAPS J. 2008;10(2):322–30.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Di Colo G, Zambito Y, Zaino C. Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration-enhancing properties, mechanism of action, safety issues. J Pharm Sci. 2008;97(5):1652–80.PubMedCrossRefGoogle Scholar
  56. Di Rienzo Businco L, Di Rienzo Businco A, D'Emilia M, Lauriello M, Coen Tirelli G. Topical versus systemic diclofenac in the treatment of temporo-mandibular joint dysfunction symptoms. Acta Otorhinolaryngol Ital. 2004;24(5):279–83.PubMedGoogle Scholar
  57. Di Stefano G, Truini A. Pharmacological treatment of trigeminal neuralgia. Expert Rev Neurother. 2017;17(10):1003–11.PubMedCrossRefGoogle Scholar
  58. Di Zenzo G, Carrozzo M, Chan LS. Urban legend series: mucous membrane pemphigoid. Oral Dis. 2014;20(1):35–54.PubMedCrossRefGoogle Scholar
  59. Dib JG. Focus on topiramate in neuropathic pain. Curr Med Res Opin. 2004;20(12):1857–61.PubMedCrossRefGoogle Scholar
  60. Dixon RB, Christy NP. On the various forms of corticosteroid withdrawal syndrome. Am J Med. 1980;68(2):224–30.PubMedCrossRefGoogle Scholar
  61. Dost F, Farah CS. Stimulating the discussion on saliva substitutes: a clinical perspective. Aust Dent J. 2013;58(1):11–7.PubMedCrossRefGoogle Scholar
  62. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53(1):3–9.PubMedCrossRefGoogle Scholar
  63. 2018
  64. Elion GB. Acyclovir: discovery, mechanism of action, and selectivity. J Med Virol Suppl. 1993;1:2–6.CrossRefGoogle Scholar
  65. Elliott T, Campbell H, Escudier M, Poate T, Nunes C, Lomer M, Mentzer A, Patel P, Shirlaw P, Brostoff J, Challacombe S, Sanderson J. Experience with anti-TNF-alpha therapy for orofacial granulomatosis. J Oral Pathol Med. 2011;40(1):14–9.PubMedCrossRefGoogle Scholar
  66. Elshibly A, Coulter WA, Millar BC, Prendergast BD, Thornhill M, Irwin C, Goldsmith CE, Moore JE. Effective oral health in infective endocarditis: efficacy of high-street mouthwashes against the viridans group streptococci. J Investig Clin Dent. 2014;5(2):151–3.PubMedCrossRefGoogle Scholar
  67. Epstein JB, Epstein JD, Epstein MS, Oien H, Truelove EL. Doxepin rinse for management of mucositis pain in patients with cancer: one week follow-up of topical therapy. Spec Care Dentist. 2008;28(2):73–7.PubMedCrossRefGoogle Scholar
  68. Epstein JB, Truelove EL, Oien H, Allison C, Le ND, Epstein MS. Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy. Oral Oncol. 2001;37(8):632–7.PubMedCrossRefGoogle Scholar
  69. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain. 2011;152(9):1988–96.PubMedCrossRefGoogle Scholar
  70. Ertz-Archambault N, Kosiorek H, Taylor GE, Kelemen K, Dueck A, Castro J, Marino R, Gauthier S, Finn L, Sproat LZ, Palmer J, Mesa RA, Al-Kali A, Foran J, Tibes R. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol. 2017;3(7):936–43.PubMedPubMedCentralCrossRefGoogle Scholar
  71. Excellence, N. I. f. H. a. C. UK NICE Guidance. 2018Google Scholar
  72. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol. 2007;57(5):737–63; quiz 764–736PubMedCrossRefGoogle Scholar
  73. Fedele S, Fung PP, Bamashmous N, Petrie A, Porter S. Long-term effectiveness of intralesional triamcinolone acetonide therapy in orofacial granulomatosis: an observational cohort study. Br J Dermatol. 2014;170(4):794–801.PubMedPubMedCentralCrossRefGoogle Scholar
  74. Fedorowicz Z, Aljufairi H, Nasser M, Outhouse TL, Pedrazzi V. Mouthrinses for the treatment of halitosis. Cochrane Database Syst Rev. 2008;4:CD006701.Google Scholar
  75. Ficarra G, Carlos R. Syphilis: the renaissance of an old disease with oral implications. Head Neck Pathol. 2009;3(3):195–206.PubMedPubMedCentralCrossRefGoogle Scholar
  76. Fleischmann RM, Caldwell JR, Roth SH, Tesser JRP, Olson W, Kamin M. Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Curr Ther Res. 2001;62(2):113–28.CrossRefGoogle Scholar
  77. Forbes JA, Calderazzo JP, Bowser MW, Foor VM, Shackleford RW, Beaver WT. A 12-hour evaluation of the analgesic efficacy of diflunisal, aspirin, and placebo in postoperative dental pain. J Clin Pharmacol. 1982;22(2–3):89–96.PubMedCrossRefGoogle Scholar
  78. Fowler JA, Shen JY, Bettinger TL. Successful use of topiramate in a patient with severe postherpetic neuralgia. Ann Pharmacother. 2009;43(1):139–42.PubMedCrossRefGoogle Scholar
  79. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol. 1984;15(3):240–4.PubMedCrossRefGoogle Scholar
  80. Fromm GH, Terrence CF, Chattha AS, Glass JD. Baclofen in trigeminal neuralgia: its effect on the spinal trigeminal nucleus: a pilot study. Arch Neurol. 1980;37(12):768–71.PubMedCrossRefGoogle Scholar
  81. Furness S, Bryan G, McMillan R, Worthington HV. Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev. 2013;8:CD009603.Google Scholar
  82. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev. 2011;12:CD008934.Google Scholar
  83. Galer BS, Rowbotham M, Perander J, Devers A, Friedman E. Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manag. 2000;19(4):287–94.CrossRefGoogle Scholar
  84. Gandhi A, Jana S, Sen KK. In-vitro release of acyclovir loaded Eudragit RLPO((R)) nanoparticles for sustained drug delivery. Int J Biol Macromol. 2014;67:478–82.PubMedCrossRefGoogle Scholar
  85. Gandolfo S, Scully C, Carrozzo M. Oral medicine. Edinburgh: Churchill Livingstone; 2006.Google Scholar
  86. Georgakopoulou EA, Scully C. Systemic use of non-biologic corticosteroids in orofacial diseases. Oral Dis. 2014;20(2):127–35.PubMedCrossRefGoogle Scholar
  87. Georgakopoulou E, Scully C. Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. Br Dent J. 2015a;218(12):671–7.PubMedCrossRefGoogle Scholar
  88. Georgakopoulou EA, Scully C. Orofacial adverse effects of biological agents. J Investig Clin Dent. 2015b;6(4):252–60.PubMedCrossRefGoogle Scholar
  89. Georgakopoulou EA, Scully C. Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents. Oral Dis. 2015c;21(3):273–82.PubMedCrossRefGoogle Scholar
  90. Germanas J, Pandya AG. Alkylating agents. Dermatol Ther. 2002;15:317–24.CrossRefGoogle Scholar
  91. Gomez-Arguelles JM, Dorado R, Sepulveda JM, Herrera A, Arrojo FG, Aragon E, Huete CR, Terron C, Anciones B. Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgia. J Clin Neurosci. 2008;15(5):516–9.PubMedCrossRefGoogle Scholar
  92. Gomez-Moreno G, Aguilar-Salvatierra A, Guardia J, Uribe-Marioni A, Cabrera-Ayala M, Delgado-Ruiz RA, Calvo-Guirado JL. The efficacy of a topical sialogogue spray containing 1% malic acid in patients with antidepressant-induced dry mouth: a double-blind, randomized clinical trial. Depress Anxiety. 2013;30(2):137–42.PubMedCrossRefGoogle Scholar
  93. Gonzalez-Moles MA, Scully C. HPA-suppressive effects of aqueous clobetasol propionate in the treatment of patients with oral lichen planus. J Eur Acad Dermatol Venereol. 2010;24(9):1055–9.PubMedGoogle Scholar
  94. Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J. 2007;13(2):1.PubMedGoogle Scholar
  95. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312(7024):169–72.PubMedPubMedCentralCrossRefGoogle Scholar
  96. Grisius MM. Salivary gland dysfunction: a review of systemic therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92(2):156–62.PubMedCrossRefGoogle Scholar
  97. Gurcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161(4):723–31.PubMedCrossRefGoogle Scholar
  98. Handbook AM. Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2018.Google Scholar
  99. Harel L, Amir J, Livni E, Straussberg R, Varsano I. Serum-sickness-like reaction associated with minocycline therapy in adolescents. Ann Pharmacother. 1996;30(5):481–3.PubMedCrossRefGoogle Scholar
  100. Haviv Y, Rettman A, Aframian D, Sharav Y, Benoliel R. Myofascial pain: an open study on the pharmacotherapeutic response to stepped treatment with tricyclic antidepressants and gabapentin. J Oral Facial Pain Headache. 2015;29(2):144–51.PubMedCrossRefGoogle Scholar
  101. Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofac Pain. 2002;16(1):64–70.PubMedPubMedCentralGoogle Scholar
  102. Hiltunen K, Vehkalahti MM, Peltola JS, Ainamo A. A 5-year follow-up of occlusal status and radiographic findings in mandibular condyles of the elderly. Int J Prosthodont. 2002;15(6):539–43.PubMedGoogle Scholar
  103. Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, Jin L. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain. 2013;14:72.PubMedPubMedCentralCrossRefGoogle Scholar
  104. Hua F, Xie H, Worthington HV, Furness S, Zhang Q, Li C. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database Syst Rev. 2016;10:CD008367.PubMedGoogle Scholar
  105. Hullah EA, Blaker PA, Marinaki AM, Escudier MP, Sanderson JD. A practical guide to the use of thiopurines in oral medicine. J Oral Pathol Med. 2015;44(10):761–8.PubMedCrossRefGoogle Scholar
  106. Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent. 2001;85(2):162–9.PubMedCrossRefGoogle Scholar
  107. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736–45.PubMedCrossRefGoogle Scholar
  108. Jackson S, Gilchrist H, Nesbitt LT Jr. Update on the dermatologic use of systemic glucocorticosteroids. Dermatol Ther. 2007;20(4):187–205.PubMedCrossRefGoogle Scholar
  109. James P, Worthington HV, Parnell C, Harding M, Lamont T, Cheung A, Whelton H, Riley P. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database Syst Rev. 2017;3:CD008676.PubMedGoogle Scholar
  110. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75(7):951–7.PubMedPubMedCentralCrossRefGoogle Scholar
  111. Jenkins S, Addy M, Wade W. The mechanism of action of chlorhexidine. A study of plaque growth on enamel inserts in vivo. J Clin Periodontol. 1988;15(7):415–24.PubMedCrossRefGoogle Scholar
  112. Jiang YC, Feng H, Lin YC, Guo XR. New strategies against drug resistance to herpes simplex virus. Int J Oral Sci. 2016;8(1):1–6.PubMedPubMedCentralCrossRefGoogle Scholar
  113. Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transplant. 2016;16(12):3490–503.PubMedCrossRefGoogle Scholar
  114. Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Beneton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P, French study group on autoimmune bullous skin diseases. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–40.PubMedCrossRefGoogle Scholar
  115. Jovanovic M, Golusin Z. Nonsteroidal Topical Immunomodulators in Allergology and Dermatology. Biomed Res Int. 2016;2016:5185303.PubMedPubMedCentralCrossRefGoogle Scholar
  116. Kanwar AJ, De D. Methotrexate for treatment of lichen planus: old drug, new indication. J Eur Acad Dermatol Venereol. 2013;27(3):e410–3.PubMedCrossRefGoogle Scholar
  117. Karpinski TM, Szkaradkiewicz AK. Chlorhexidine – pharmaco-biological activity and application. Eur Rev Med Pharmacol Sci. 2015;19(7):1321–6.PubMedGoogle Scholar
  118. Kaur S, Pandhi P, Dutta P. Painful diabetic neuropathy: an update. Ann Neurosci. 2011;18(4):168–75.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Kim J, Chan JJ. Cyclophosphamide in dermatology. Australas J Dermatol. 2017;58(1):5–17.PubMedCrossRefGoogle Scholar
  120. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev. 2003;1:CD004056.Google Scholar
  121. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol. 1996;132(8):934–9.PubMedCrossRefGoogle Scholar
  122. Kopsky DJ, Liebregts R, Keppel Hesselink JM. Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline. Case Rep Med. 2012;2012:471835.PubMedPubMedCentralCrossRefGoogle Scholar
  123. Kovac M, Mitic G, Kovac Z. Miconazole and nystatin used as topical antifungal drugs interact equally strongly with warfarin. J Clin Pharm Ther. 2012;37(1):45–8.PubMedCrossRefGoogle Scholar
  124. Krishna MT, York M, Chin T, Gnanakumaran G, Heslegrave J, Derbridge C, Huissoon A, Diwakar L, Eren E, Crossman RJ, Khan N, Williams AP. Multi-centre retrospective analysis of anaphylaxis during general anaesthesia in the United Kingdom: aetiology and diagnostic performance of acute serum tryptase. Clin Exp Immunol. 2014;178(2):399–404.PubMedPubMedCentralCrossRefGoogle Scholar
  125. Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011;34(6):241–7.PubMedCrossRefGoogle Scholar
  126. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008;66(8):1644–51.PubMedCrossRefGoogle Scholar
  127. Kuten-Shorrer M, Treister NS, Stock S, Kelley JM, Ji YD, Woo SB, Lerman MA, Palmason S, Sonis ST, Villa A. Topical Clonazepam Solution for the Management of Burning Mouth Syndrome: A Retrospective Study. J Oral Facial Pain Headache. 2017;31(3):257–63.PubMedCrossRefGoogle Scholar
  128. Lee YC, Shin SY, Kim SW, Eun YG. Intralesional injection versus mouth rinse of triamcinolone acetonide in oral lichen planus: a randomized controlled study. Otolaryngol Head Neck Surg. 2013;148(3):443–9.PubMedCrossRefGoogle Scholar
  129. Lehner T, Lyne C. Adrenal function during topical oral corticosteroid treatment. Br Med J. 1969;4(5676):138–41.PubMedPubMedCentralCrossRefGoogle Scholar
  130. Lenz W. A short history of thalidomide embryopathy. Teratology. 1988;38(3):203–15.PubMedCrossRefGoogle Scholar
  131. Levell NJ, Munro CS, Marks JM. Severe lichen planus clears with very low-dose cyclosporin. Br J Dermatol. 1992;127(1):66–7.PubMedCrossRefGoogle Scholar
  132. Levine MJ, Aguirre A, Hatton MN, Tabak LA. Artificial salivas: present and future. J Dent Res. 1987;66 Spec No:693–8.PubMedCrossRefGoogle Scholar
  133. Limited TG. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2018.Google Scholar
  134. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.PubMedPubMedCentralCrossRefGoogle Scholar
  135. Lynch ME, Clark AJ, Sawynok J. A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin J Pain. 2003;19(5):323–8.PubMedCrossRefGoogle Scholar
  136. Lyu X, Zhao C, Yan ZM, Hua H. Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1161–71.PubMedPubMedCentralCrossRefGoogle Scholar
  137. Macura AB. The influence of some antifungal drugs on in vitro adherence of Candida albicans to human buccal epithelial cells. Mycoses. 1988;31(7):371–6.PubMedCrossRefPubMedCentralGoogle Scholar
  138. Madan V, Griffiths CE. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther. 2007;20(4):239–50.PubMedCrossRefPubMedCentralGoogle Scholar
  139. Mansh M, Binstock M, Williams K, Hafeez F, Kim J, Glidden D, Boettger R, Hays S, Kukreja J, Golden J, Asgari MM, Chin-Hong P, Singer JP, Arron ST. Voriconazole Exposure and Risk of Cutaneous Squamous Cell Carcinoma, Aspergillus Colonization, Invasive Aspergillosis and Death in Lung Transplant Recipients. Am J Transplant. 2016;16(1):262–70.PubMedCrossRefPubMedCentralGoogle Scholar
  140. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puechal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270–6.PubMedCrossRefPubMedCentralGoogle Scholar
  141. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009;(1):CD006263.Google Scholar
  142. Martini MZ, Galletta VC, Pereira EM, De Sousa SC, Lemos CA, Migliari DA. Orofacial granulomatosis of the lip: a report of 2 cases with histological and immunohistochemical analyses and intralesional corticotherapy. Minerva Stomatol. 2010;59(10):579–81.PubMedPubMedCentralGoogle Scholar
  143. Mattsson U, Magnusson B, Jontell M. Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(1):e19–25.PubMedCrossRefPubMedCentralGoogle Scholar
  144. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, Dubner R. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37(4):589–96.PubMedCrossRefPubMedCentralGoogle Scholar
  145. Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis. 2013;19(4):327–46.PubMedCrossRefPubMedCentralGoogle Scholar
  146. McCarty M, Fivenson D. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents. J Am Acad Dermatol. 2014;71(3):475–9.PubMedCrossRefPubMedCentralGoogle Scholar
  147. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–94.PubMedCrossRefGoogle Scholar
  148. McMillan R, Taylor J, Shephard M, Ahmed R, Carrozzo M, Setterfield J, Grando S, Mignogna M, Kuten-Shorrer M, Musbah T, Elia A, McGowan R, Kerr AR, Greenberg MS, Hodgson T, Sirois D. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucocutaneous pemphigus vulgaris. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):132–142 e161.PubMedCrossRefPubMedCentralGoogle Scholar
  149. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia. 1993;48(4):281–5.PubMedCrossRefGoogle Scholar
  150. Meijer JM, Pijpe J, Bootsma H, Vissink A, Kallenberg CG. The future of biologic agents in the treatment of Sjogren's syndrome. Clin Rev Allergy Immunol. 2007;32(3):292–7.PubMedPubMedCentralCrossRefGoogle Scholar
  151. Mejersjo C, Wenneberg B. Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial. J Oral Rehabil. 2008;35(10):729–38.PubMedCrossRefGoogle Scholar
  152. Mercadante V, Al Hamad A, Lodi G, Porter S, Fedele S. Interventions for the management of radiotherapy-induced xerostomia and hyposalivation: A systematic review and meta-analysis. Oral Oncol. 2017;66:64–74.PubMedCrossRefGoogle Scholar
  153. Merrill RL, Dionne RA. Medications for Management of Chronic, Non-Odontogenic Pain. In: Dowd F, Johnson B, Mariotti A, editors. Pharmacology and Therapeutics for Dentistry. St. Louis: Elsevier; 2017.Google Scholar
  154. Mignogna MD, Fedele S, Lo Russo L, Adamo D, Satriano RA. Effectiveness of small-volume, intralesional, delayed-release triamcinolone injections in orofacial granulomatosis: a pilot study. J Am Acad Dermatol. 2004;51(2):265–8.PubMedCrossRefGoogle Scholar
  155. Mignogna MD, Pollio A, Leuci S, Ruoppo E, Fortuna G. Clinical behaviour and long-term therapeutic response in orofacial granulomatosis patients treated with intralesional triamcinolone acetonide injections alone or in combination with topical pimecrolimus 1%. J Oral Pathol Med. 2013;42(1):73–81.PubMedCrossRefGoogle Scholar
  156. Miki A, Ohtani H, Sawada Y. Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model. J Clin Pharm Ther. 2011;36(6):642–50.PubMedCrossRefGoogle Scholar
  157. Mimouni D, Nousari CH. Inhibitor of purine and pyirimidine synthesis: mycophenolate, azathioprine and leflunomide. Dermatol Ther. 2002;15:311–6.CrossRefGoogle Scholar
  158. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4(3):252–6.PubMedCrossRefGoogle Scholar
  159. Moon C, Chae YK, Lee J. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood). 2010;235(8):907–20.CrossRefGoogle Scholar
  160. Morra ME, Elgebaly A, Elmaraezy A, Khalil AM, Altibi AM, Vu TL, Mostafa MR, Huy NT, Hirayama K. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;17(1):63.PubMedPubMedCentralCrossRefGoogle Scholar
  161. Nagashima W, Kimura H, Ito M, Tokura T, Arao M, Aleksic B, Yoshida K, Kurita K, Ozaki N. Effectiveness of duloxetine for the treatment of chronic nonorganic orofacial pain. Clin Neuropharmacol. 2012;35(6):273–7.PubMedCrossRefPubMedCentralGoogle Scholar
  162. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006;13 Suppl 4:35–40.PubMedCrossRefPubMedCentralGoogle Scholar
  163. NHS England. Clinical commissioning policy: rituximab for immunobullous disease. Last accessed July 2018.
  164. Niedner R. Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents. Dermatology. 1997;195 Suppl 2:89–92.PubMedCrossRefPubMedCentralGoogle Scholar
  165. Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369(8):754–62.PubMedCrossRefPubMedCentralGoogle Scholar
  166. O'Neill ID, Scully C. Biologics in oral medicine: oral Crohn's disease and orofacial granulomatosis. Oral Dis. 2012;18(7):633–8.PubMedCrossRefPubMedCentralGoogle Scholar
  167. O'Neill ID, Scully C. Biologics in oral medicine: Sjogren syndrome. Oral Dis. 2013;19(2):121–7.PubMedCrossRefPubMedCentralGoogle Scholar
  168. Obermann M, Mueller D, Yoon MS, Pageler L, Diener H, Katsarava Z. Migraine with isolated facial pain: a diagnostic challenge. Cephalalgia. 2007;27(11):1278–82.PubMedCrossRefGoogle Scholar
  169. Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. Neurology. 2018;90(7):e559–64.PubMedCrossRefGoogle Scholar
  170. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–65.PubMedCrossRefGoogle Scholar
  171. O′Reilly RA, Goulart DA, Kunze KL et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther. 1992;51:656–667.PubMedCrossRefGoogle Scholar
  172. Overman RA, Toliver JC, Yeh JY, Gourlay ML, Deal CL. United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2014;66(11):1644–52.CrossRefGoogle Scholar
  173. Palmberger TF, Hombach J, Bernkop-Schnurch A. Thiolated chitosan: development and in vitro evaluation of an oral delivery system for acyclovir. Int J Pharm. 2008;348(1–2):54–60.PubMedCrossRefGoogle Scholar
  174. Pamba A, Richardson ND, Carter N, Duparc S, Premji Z, Tiono AB, Luzzatto L. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood. 2012;120(20):4123–33.PubMedCrossRefPubMedCentralGoogle Scholar
  175. Pemberton MN. Allergy to Chlorhexidine. Dent Update. 2016;43(3):272–4.PubMedCrossRefPubMedCentralGoogle Scholar
  176. Perret LJ, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in dermatology. Australas J Dermatol. 2014;55(2):111–8.PubMedCrossRefPubMedCentralGoogle Scholar
  177. Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FK, Kallenberg CG, Vissink A, Ihrler S. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. Arthritis Rheum. 2009;60(11):3251–6.PubMedCrossRefPubMedCentralGoogle Scholar
  178. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55(2):459–72.PubMedCrossRefPubMedCentralGoogle Scholar
  179. Preshaw PM. Host response modulation in periodontics. Periodontol. 2008;48:92–110.CrossRefGoogle Scholar
  180. Preshaw PM, Grainger P, Bradshaw MH, Mohammad AR, Powala CV, Nolan A. Subantimicrobial dose doxycycline in the treatment of recurrent oral aphthous ulceration: a pilot study. J Oral Pathol Med. 2007;36(4):236–40.PubMedCrossRefPubMedCentralGoogle Scholar
  181. Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging. 1995;7(4):317–28.PubMedCrossRefPubMedCentralGoogle Scholar
  182. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274–83.PubMedCrossRefPubMedCentralGoogle Scholar
  183. Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc. 2011;86(10):1009–26.PubMedPubMedCentralCrossRefGoogle Scholar
  184. Restivo DA, Lauria G, Marchese-Ragona R, Vigneri R. Botulinum Toxin for Burning Mouth Syndrome. Ann Intern Med. 2017;166(10):762–3.PubMedCrossRefPubMedCentralGoogle Scholar
  185. Restivo DA, Tinazzi M, Patti F, Palmeri A, Maimone D. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003;61(5):719–20.PubMedCrossRefPubMedCentralGoogle Scholar
  186. Ring J, Möhrenschlager M, Henkel V. The US FDA ‘black box’ warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008;31(3):185–98.PubMedCrossRefPubMedCentralGoogle Scholar
  187. Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol. 2003;139(10):1259–62.PubMedCrossRefGoogle Scholar
  188. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol. 2000;6(5):250–7.PubMedCrossRefGoogle Scholar
  189. Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behcet's syndrome. Cochrane Database Syst Rev. 2000;(2):CD001084.Google Scholar
  190. Samaranayake LP, Keung Leung W, Jin L. Oral mucosal fungal infections. Periodontol. 2009;49:39–59.CrossRefGoogle Scholar
  191. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50(7):2240–5.PubMedCrossRefGoogle Scholar
  192. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med. 2007;23(3):615–32, vii–viiiPubMedPubMedCentralCrossRefGoogle Scholar
  193. Schreier H, Erdos G, Reimer K, Konig B, Konig W, Fleischer W. Molecular effects of povidone-iodine on relevant microorganisms: an electron-microscopic and biochemical study. Dermatology. 1997;195 Suppl 2:111–6.PubMedCrossRefGoogle Scholar
  194. Scottish Dental Clinical Effectiveness Programme (SDCEP). Drug prescribing for dentistry. 3rd ed. 2016.
  195. Scully C, Bagan J. Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac Surg. 2008;46(2):90–5.PubMedCrossRefGoogle Scholar
  196. Scully C, Felix DH. Oral medicine – update for the dental practitioner. Aphthous and other common ulcers. Br Dent J. 2005;199(5):259–64.PubMedCrossRefPubMedCentralGoogle Scholar
  197. Selvaggi G, Monstrey S, Van Landuyt K, Hamdi M, Blondeel P. The role of iodine in antisepsis and wound management: a reappraisal. Acta Chir Belg. 2003;103(3):241–7.PubMedCrossRefGoogle Scholar
  198. Seymour RA, Hogg SD. Antibiotics and chemoprophylaxis. Periodontol. 2008;46:80–108.CrossRefGoogle Scholar
  199. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford). 2007;46(5):736–41.CrossRefGoogle Scholar
  200. Sharav Y, Singer E, Schmidt E, Dionne RA, Dubner R. The analgesic effect of amitriptyline on chronic facial pain. Pain. 1987;31(2):199–209.PubMedCrossRefGoogle Scholar
  201. Shen S, O'Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol. 2012;53(1):1–18.PubMedCrossRefGoogle Scholar
  202. Shorvon SD, Perucca E, Engel J. The treatment of epilepsy. Oxford: Wiley; 2015.CrossRefGoogle Scholar
  203. Sidebottom A, Maxwell S. The medical and surgical management of trigeminal neuralgia. J Clin Pharm Ther. 1995;20(1):31–5.PubMedCrossRefGoogle Scholar
  204. Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache. 2017;57(1):165–78.PubMedCrossRefGoogle Scholar
  205. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain. 1999;83(1):85–90.PubMedCrossRefGoogle Scholar
  206. Singer E, Dionne R. A controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain. J Orofac Pain. 1997;11(2):139–46.PubMedPubMedCentralGoogle Scholar
  207. Slots J. Low-cost periodontal therapy. Periodontol. 2012;60(1):110–37.CrossRefGoogle Scholar
  208. Smith MR, Cooper SC. Mycophenolate mofetil therapy in the management of inflammatory bowel disease – a retrospective case series and review. J Crohns Colitis. 2014;8(8):890–7.PubMedCrossRefGoogle Scholar
  209. Sneader W. Drug discovery: the evolution of modern medicines. Chichester: Wiley; 1989.Google Scholar
  210. Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51(8):889–902.CrossRefPubMedPubMedCentralGoogle Scholar
  211. Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician. 2000;61(8):2437–44, 2447–2438PubMedGoogle Scholar
  212. Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med. 2012;366(26):2492–501.PubMedCrossRefGoogle Scholar
  213. Stow PJ, Glynn CJ, Minor B. EMLA cream in the treatment of post-herpetic neuralgia. Efficacy and pharmacokinetic profile. Pain. 1989;39(3):301–5.PubMedCrossRefGoogle Scholar
  214. Strathie Page SJ, Tait CP. Mycophenolic acid in dermatology a century after its discovery. Australas J Dermatol. 2015;56(1):77–83.PubMedCrossRefGoogle Scholar
  215. Striano P, Striano S. Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. Drugs Today (Barc). 2008;44(5):353–68.CrossRefGoogle Scholar
  216. Svensson P, Wang K, Arendt-Nielsen L. Effect of muscle relaxants on experimental jaw-muscle pain and jaw-stretch reflexes: a double-blind and placebo-controlled trial. Eur J Pain. 2003;7(5):449–56.PubMedCrossRefGoogle Scholar
  217. Ta LE, Dionne RA. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. Pain. 2004;111(1–2):13–21.PubMedCrossRefGoogle Scholar
  218. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53(9):2102–7.PubMedCrossRefGoogle Scholar
  219. Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000;68(2):186–90.PubMedPubMedCentralCrossRefGoogle Scholar
  220. Tan HH, Goh CL. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol. 2006;7(1):13–29.PubMedCrossRefGoogle Scholar
  221. Tao Y, Lu Y, Sun Y, Gu B, Lu W, Pan J. Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. Int J Pharm. 2009;378(1–2):30–6.PubMedCrossRefGoogle Scholar
  222. Tedesco D, Haragsim L. Cyclosporine: a review. J Transp Secur. 2012;2012:230386.Google Scholar
  223. Thie NM, Prasad NG, Major PW. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. J Rheumatol. 2001;28(6):1347–55.PubMedGoogle Scholar
  224. Thompson DF, Brooks KG. Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther. 2015;40(5):496–503.PubMedCrossRefGoogle Scholar
  225. Thomson WM, Lawrence HP, Broadbent JM, Poulton R. The impact of xerostomia on oral-health-related quality of life among younger adults. Health Qual Life Outcomes. 2006;4:86.PubMedPubMedCentralCrossRefGoogle Scholar
  226. Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev. 2011;(7):CD001168.Google Scholar
  227. Ting PT, Freiman A. The story of Clostridium botulinum: from food poisoning to Botox. Clin Med (Lond). 2004;4(3):258–61.CrossRefGoogle Scholar
  228. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004;51(1):9–13.PubMedCrossRefGoogle Scholar
  229. Tomson T, Battino D, Perucca E. The remarkable story of valproic acid. Lancet Neurol. 2016;15(2):141.PubMedCrossRefGoogle Scholar
  230. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004;26(9):1355–67.PubMedCrossRefGoogle Scholar
  231. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;(1):Cd004257.Google Scholar
  232. Troullos ES, Hargreaves KM, Butler DP, Dionne RA. Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and flurbiprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus. J Oral Maxillofac Surg. 1990;48(9):945–52.PubMedCrossRefGoogle Scholar
  233. van den Berghe LI, de Boever JA, Schautteet H. Double-blind clinical study of Piroxicam as adjuvant in the treatment of the pain and dysfunction of the temporomandibular joints. Cranio. 1986;4(4):351–6.PubMedCrossRefGoogle Scholar
  234. Veilleux MS, Shear NH. Biologics in patients with skin diseases. J Allergy Clin Immunol. 2017;139(5):1423–30.PubMedCrossRefGoogle Scholar
  235. Villa A, Wolff A, Aframian D, Vissink A, Ekstrom J, Proctor G, McGowan R, Narayana N, Aliko A, Sia YW, Joshi RK, Jensen SB, Kerr AR, Dawes C, Pedersen AM. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment. Clin Oral Investig. 2015;19(7):1563–80.PubMedCrossRefGoogle Scholar
  236. Volcy M, Rapoport AM, Tepper SJ, Sheftell FD, Bigal ME. Persistent idiopathic facial pain responsive to topiramate. Cephalalgia. 2006;26(4):489–91.PubMedCrossRefGoogle Scholar
  237. von Bultzingslowen I, Sollecito TP, Fox PC, Daniels T, Jonsson R, Lockhart PB, Wray D, Brennan MT, Carrozzo M, Gandera B, Fujibayashi T, Navazesh M, Rhodus NL, Schiodt M. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl:S57 e51–15.Google Scholar
  238. Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem. 2009;9(1):71–8.PubMedCrossRefGoogle Scholar
  239. Vujevich J, Zirwas M. Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab. Cutis. 2005;76(2):129–32.PubMedGoogle Scholar
  240. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, Ayanian JZ, Nallamothu BK. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.PubMedPubMedCentralCrossRefGoogle Scholar
  241. Wee JS, Shirlaw PJ, Challacombe SJ, Setterfield JF. Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients. Br J Dermatol. 2012;167(1):36–43.PubMedCrossRefGoogle Scholar
  242. Wiffen PJ, Derry S, Lunn MP, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;(8):CD008314.Google Scholar
  243. Williams K, Arron ST. Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma. JAMA Dermatol. 2016;152(6):719–20.PubMedCrossRefGoogle Scholar
  244. Wise M, Callen JP. Azathioprine: a guide for the management of dermatology patients. Dermatol Ther. 2007;20(4):206–15.PubMedCrossRefGoogle Scholar
  245. Wojenski DJ, Bartoo GT, Merten JA, Dierkhising RA, Barajas MR, El-Azhary RA, Wilson JW, Plevak MF, Hogan WJ, Litzow MR, Patnaik MM, Wolf RC, Hashmi SK. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. Transpl Infect Dis. 2015;17(2):250–8.PubMedCrossRefGoogle Scholar
  246. Wong SSW, Samaranayake LP, Seneviratne CJ. In pursuit of the ideal antifungal agent for Candida infections: high-throughput screening of small molecules. Drug Discov Today. 2014;19(11):1721–30.PubMedCrossRefGoogle Scholar
  247. Woo SB, Challacombe SJ. Management of recurrent oral herpes simplex infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl:S12 e11–8.Google Scholar
  248. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153(2):254–73.PubMedCrossRefGoogle Scholar
  249. Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev. 2007;28(4):365–86.PubMedCrossRefGoogle Scholar
  250. Xia J, Li C, Hong Y, Yang L, Huang Y, Cheng B. Short-term clinical evaluation of intralesional triamcinolone acetonide injection for ulcerative oral lichen planus. J Oral Pathol Med. 2006;35(6):327–31.PubMedCrossRefGoogle Scholar
  251. Ylikontiola L, Sorsa T, Hayrinen-Immonen R, Salo T. Doxymycine-cyanoacrylate treatment of recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83(3):329–33.PubMedCrossRefGoogle Scholar
  252. Yuson CL, Katelaris CH, Smith WB. Cephalosporin allergy’ label is misleading. Aust Prescr. 2018;41(2):37–41.PubMedPubMedCentralCrossRefGoogle Scholar
  253. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997;73(2):223–30.PubMedCrossRefGoogle Scholar
  254. Zhang LW, Fu JY, Hua H, Yan ZM. Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta-analysis. Oral Dis. 2016;22(3):185–95.PubMedCrossRefGoogle Scholar
  255. Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015;75(3):271–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sandra Goncalves
    • 1
  • Ray A. Dionne
    • 2
  • Geraldine Moses
    • 3
  • Marco Carrozzo
    • 4
    Email author
  1. 1.Oral Medicine DepartmentCharles Clifford Dental HospitalSheffieldUK
  2. 2.Department of Pharmacology and Toxicology, Brody School of Medicine, and Department of Foundational SciencesSchool of Dental Medicine, East Carolina UniversityGreenvilleUSA
  3. 3.Academic Practice UnitPharmacy Services, Mater Public HospitalSouth BrisbaneAustralia
  4. 4.Center for Oral Health Research, Department of Oral MedicineSchool of Dental Sciences, Newcastle UniversityNewcastle upon TyneUK

Section editors and affiliations

  • Michael J. McCullough
    • 1
  1. 1.Oral Anatomy, Medicine, and Surgery Section, Melbourne, Dental School, Faculty of Medicine, Dentistry & Health, SciencesThe University of MelbourneCarltonAustralia

Personalised recommendations